MB49 Cells
USD$550.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | The MB49 cell line is a murine model derived from the C57BL/6 mouse bladder epithelial cells. It was originally developed to study bladder cancer, providing a platform for examining the biological and molecular characteristics of urothelial carcinoma. The cell line was established through the chemical induction of bladder tumors using the carcinogen 7,12-dimethylbenz[a]anthracene (DMBA), as detailed in early research studies. MB49 cells exhibit a tumorigenic phenotype when transplanted into syngeneic mice, forming urothelial carcinomas. These tumors are often poorly differentiated and can display mixed morphologies, including spindle-shaped cells and adenocarcinomatous areas, which resemble aggressive bladder cancer subtypes seen in human pathology. Further research has led to the development of MB49-I, a more invasive subline of MB49. This subline was generated after 13 consecutive in vivo passages, enhancing its invasive and metastatic potential. MB49-I cells exhibit increased proteolytic activity, particularly in enzymes such as cathepsin B, matrix metalloproteinase 9 (MMP-9), and urokinase-type plasminogen activator (uPA). These enzymes contribute to the breakdown of extracellular matrix components, facilitating the invasion and metastasis of tumor cells. The MB49-I subline, when inoculated orthotopically into the bladder of syngeneic mice, leads to the formation of highly invasive bladder tumors, making it a valuable model for studying tumor progression and testing anti-cancer therapeutics aimed at preventing invasion and metastasis. This MB49 model, including the MB49-I variant, is instrumental in understanding the molecular mechanisms underlying bladder cancer progression and in developing new therapeutic strategies. The model closely mimics human bladder cancer, particularly in its ability to simulate the invasive and metastatic characteristics of the disease, thereby providing a robust system for preclinical studies. |
|---|---|
| Organism | Mouse |
| Tissue | Urinary bladder |
| Disease | Mouse bladder transitional cell carcinoma |
| Synonyms | MB-49 |
Characteristics
| Breed/Subspecies | C57BL/ICRF-a(t) |
|---|---|
| Age | Adult |
| Gender | Male |
| Morphology | Epithelial |
| Growth properties | Adherent |
Regulatory Data
| Citation | MB49 (Cytion catalog number 305240) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 10090 |
| CellosaurusAccession | CVCL_7076 |
Biomolecular Data
| Karyotype | Has lost chromosome Y |
|---|
Handling
| Culture Medium | DMEM, w: 4.5 g/L Glucose, w: 4 mM L-Glutamine, w: 3.7 g/L NaHCO3, w: 1.0 mM Sodium pyruvate (Cytion article number 820300a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Dissociation Reagent | Accutase |
| Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305240-270824 | Certificate of Analysis | 23. May. 2025 | 305240 |